Minimal Change Disease

Minimal Change Disease (MCD) is the most common cause of nephrotic syndrome in children (80–90%) and an important cause in adults (20–25%). It is characterized by normal light microscopy, diffuse podocyte foot process effacement on electron microscopy, and absence of immune deposits on immunofluorescence. Despite its name, minimal change refers to light microscopy findings — electron microscopy reveals extensive podocyte injury. MCD typically responds dramatically to corticosteroids, but relapsing disease is common.

Table of Contents

1. Overview
2. Epidemiology
3. Pathophysiology
4. Clinical Presentation
5. Diagnosis and Biopsy Findings
6. Treatment — Initial Corticosteroid Therapy
7. Treatment — Frequent Relapsers and Steroid-Resistant Disease
8. Secondary Causes of MCD
9. MCD in Adults vs. Children
10. Prognosis
11. Research Papers (PubMed searches)
12. References
13. Featured Videos

Overview

Minimal Change Disease (MCD) is a glomerulopathy causing nephrotic syndrome via diffuse podocyte foot process effacement without immune deposits. It is the most common cause of nephrotic syndrome in children (80–90% of pediatric nephrotic syndrome under age 10; decreasing proportion in adolescents and adults). In adults, MCD accounts for 20–25% of primary nephrotic syndrome.

The name is a misnomer — light microscopy appears normal, but electron microscopy reveals near-total podocyte foot process effacement across all glomeruli. The disease is immune-mediated, likely involving T-lymphocyte dysfunction producing a circulating permeability factor (not yet definitively identified) that injures podocytes.

Idiopathic MCD responds to corticosteroids in 90% of children and 75–80% of adults, but relapses are frequent. Long-term kidney prognosis is generally excellent if remission is maintained, unlike FSGS which MCD can sometimes be confused with or progress to.

Back to Table of Contents

Epidemiology

Peak incidence in children ages 2–8 years (boys > girls 2:1 under age 6; equal over age 6). Annual incidence: 1–3 cases per 100,000 children per year in Western countries; higher in South Asian children. In adults: peak ages 20–30 (idiopathic MCD) and then again over 60 (secondary MCD from NSAIDs or lymphoma).

MCD accounts for 90% of childhood nephrotic syndrome under age 6, and approximately 50% in ages 6–12. Overall excellent prognosis with the majority achieving long-term remission. Fewer than 1% progress to end-stage renal disease (ESRD) without a misdiagnosis — most such cases reflect underlying FSGS misread as MCD on an inadequate biopsy sample.

Back to Table of Contents

Pathophysiology

The precise mechanism remains unclear, but current evidence supports a T-lymphocyte mediated disorder:

• T-cell dysfunction: CD4+ T helper cell imbalance with Th2 predominance and reduced regulatory T-cells (Tregs); elevated IL-4, IL-13, and IL-21 production. These cytokines may directly injure podocyte slit diaphragms.
• Circulating permeability factor: A soluble factor (possibly IL-13, hemopexin, cardiotrophin-like cytokine, or CD80-related factor) produced by dysregulated T-cells injures podocytes, causing foot process effacement and proteinuria.
• B-cell and antibody role: FSGS-like antibodies (anti-nephrin) are now implicated in some MCD/FSGS overlap; rituximab response suggests a B-cell contribution.
• CD80 (B7-1) upregulation on podocytes: Detected in MCD but disputed as a primary driver; CTLA4-Ig (abatacept) trials have been based on this hypothesis.
• Podocyte foot process effacement: Disruption of the slit diaphragm (nephrin-podocin complex) leads to massive loss of selective glomerular permeability, producing heavy proteinuria, albumin loss, hypoalbuminemia, reduced oncotic pressure, and edema.
• Normal light microscopy and absence of immune deposits (no IgG, IgA, IgM, or C3 on immunofluorescence): these findings distinguish MCD from membranous nephropathy, FSGS, and lupus nephritis.

Back to Table of Contents

Clinical Presentation

Nephrotic syndrome is the hallmark presentation:

• Heavy proteinuria (>3.5 g/day in adults; >40 mg/m²/hr in children): the most dramatic finding; frothy urine.
• Hypoalbuminemia (<3.0 g/dL typically; may fall to 1.0–1.5 g/dL in severe MCD): drives edema and ascites.
• Edema: periorbital edema (especially in the morning, often the first sign noticed by parents in children); dependent edema; anasarca in severe cases; ascites; pleural effusions.
• Hyperlipidemia (LDL and VLDL elevation): the liver compensates for albumin loss by increasing apolipoprotein production; lipid-lowering therapy is needed during prolonged nephrotic phases.
• Lipiduria: oval fat bodies, fatty casts (Maltese cross birefringence on polarized light).
• Hypertension: less prominent in MCD than in FSGS; more common in adults.
• Reduced eGFR at presentation: uncommon in childhood MCD but occurs in 20–30% of adults with MCD; usually resolves with remission.
• Thromboembolism risk: nephrotic syndrome causes urinary loss of antithrombin III plus protein C and S, creating a hypercoagulable state leading to deep vein thrombosis, pulmonary embolism, and renal vein thrombosis; risk is higher in adults than children.
• Infections: loss of opsonins (factor B, properdin) increases susceptibility to encapsulated organisms; pneumococcal peritonitis is a classic complication in children — ensure pneumococcal vaccination.

Back to Table of Contents

Diagnosis and Biopsy Findings

In children ages 1–8 with classic nephrotic syndrome, empirical steroid therapy is appropriate without prior biopsy (presumptive MCD; over 90% respond). Biopsy indications in children: age <1 or >10 years, hematuria, hypertension, low C3, family history of renal disease, or steroid resistance at 4–8 weeks.

In adults: biopsy is always required before treatment to distinguish MCD from FSGS, membranous nephropathy, and secondary causes.

Biopsy findings:

• Light microscopy: NORMAL — this is the defining feature. No hypercellularity, no basement membrane thickening, no immune deposits.
• Immunofluorescence: NEGATIVE or trace non-specific deposits. True MCD has no immune deposits.
• Electron microscopy: DIFFUSE podocyte foot process effacement (>75–90% of foot processes obliterated); microvillous transformation of podocytes. This is the diagnostic hallmark.

Lab findings: heavy proteinuria on urine dipstick (3–4+) and 24-hour collection; hypoalbuminemia; hyperlipidemia; normal complement (C3, C4); normal anti-dsDNA, ANCA, and anti-GBM. Hematuria is absent or minimal (microscopic hematuria in <25%; gross hematuria is atypical — reconsider FSGS).

Back to Table of Contents

Treatment — Initial Corticosteroid Therapy

For idiopathic MCD, prednisone (or prednisolone) is first-line:

• Children: 2 mg/kg/day (max 60 mg/day) for 4–6 weeks, then 1.5 mg/kg on alternate days for 4–6 weeks, then taper. Complete remission (protein-free urine) in 90% within 4–6 weeks. Earlier response correlates with better prognosis.
• Adults: 1 mg/kg/day (max 80 mg/day) for a minimum of 4 weeks, extending up to 16 weeks before declaring steroid resistance (adults respond more slowly). Alternate-day dosing after initial response. Response rate 75–80% in adults.
• Complete remission defined as: urine protein <4 mg/m²/hr (<0.3 g/day in adults; trace or negative dipstick) for 3 consecutive days.
• Relapse: return of proteinuria (2+ dipstick for 3 consecutive days or urine PCR >0.2) after remission. Re-treat with prednisone at the same starting dose.

Supportive measures:

• Edema management: sodium restriction (2 g/day); loop diuretics (furosemide) for symptomatic edema — use cautiously to avoid volume depletion and acute kidney injury.
• Anticoagulation: LMWH if albumin <2.0 g/dL with immobility or additional risk factors; consider warfarin for renal vein thrombosis.

Back to Table of Contents

Treatment — Frequent Relapsers and Steroid-Resistant Disease

Frequently relapsing MCD (2 or more relapses in 6 months, or 4 or more in 12 months) and steroid-dependent MCD (relapse on 15 mg/day or less of prednisone, or within 14 days of stopping):

• Cyclophosphamide (CYC): 2–3 mg/kg/day for 8–12 weeks (total cumulative dose limit approximately 200 mg/kg lifetime). Induces sustained remission in 50–60%; higher relapse rates with shorter courses. Monitor CBC and urine for hemorrhagic cystitis. Gonadotoxic — important consideration in children and young adults.
• Mycophenolate mofetil (MMF): 1–2 g/day for 1–2 years. Steroid-sparing in frequently relapsing MCD; relapse is common after stopping. Better tolerated than cyclophosphamide; not gonadotoxic; preferred in children and women of childbearing age.
• Calcineurin inhibitors (CNIs) — cyclosporine or tacrolimus: highly effective for steroid-dependent MCD. Tacrolimus (0.1–0.15 mg/kg/day) is often preferred due to fewer cosmetic side effects than cyclosporine (which causes gingival hyperplasia and hirsutism). Maintains remission in 80–85% while on therapy; frequent relapse after stopping (CNI-dependent disease is common).
• Rituximab (anti-CD20): IV 375 mg/m² for 1–4 doses; effective in steroid-dependent and frequently relapsing MCD. Relapse-free at 2 years approximately 50%; repeat dosing is possible. Mechanism may involve B-cell depletion interrupting the T-cell dysregulation cascade.

Steroid-resistant MCD — failure to achieve remission after 16 weeks of steroids: re-biopsy to exclude FSGS (sampling error — MCD and FSGS can co-exist, or an early FSGS lesion may have been missed on initial biopsy). Treat as per FSGS protocol (CNI plus steroids).

Back to Table of Contents

Secondary Causes of MCD

Secondary MCD should always be considered, especially in adults:

• NSAIDs (ibuprofen, naproxen, others): the most common drug cause; especially in older adults; interstitial nephritis may co-exist.
• Hodgkin's lymphoma: MCD is a well-recognized paraneoplastic syndrome associated with Hodgkin's lymphoma; treatment of the lymphoma resolves MCD. All adult MCD patients need a thorough malignancy workup including lymph node examination, CBC, and CT of the chest, abdomen, and pelvis.
• Allergic reactions: bee stings, poison ivy, and certain foods have been implicated in isolated cases.
• Infections: HIV (more commonly causes HIVAN or collapsing FSGS); hepatitis B; syphilis; CMV.
• Other drugs: lithium, gold, mercury, penicillamine, interferon-alpha.

Evaluation should include CBC, CT scan, and PET scan if lymphoma is suspected, along with a thorough medication review.

Back to Table of Contents

MCD in Adults vs. Children

Adults with MCD differ from children in several important ways:

• Slower steroid response: up to 16 weeks required in adults vs. 4–6 weeks in children.
• Biopsy requirement: always required in adults vs. selective use in children.
• Higher frequency of secondary MCD: NSAIDs and lymphoma are important causes in adults, rare in children.
• More frequent AKI at presentation: 20–30% of adults vs. uncommon in children.
• Higher thromboembolism risk: anticoagulation thresholds are lower in adults.
• CNI-dependence: more common in adults than in children.

FSGS is approximately 10 times more likely than MCD in adults presenting with nephrotic syndrome, compared to children where MCD predominates — hence biopsy is crucial in adults to avoid treating FSGS as MCD.

Transition to adult nephrology care is an important consideration for pediatric patients who continue to have disease into adulthood.

Back to Table of Contents

Prognosis

Children: excellent prognosis. The majority achieve long-term remission after initial or subsequent corticosteroid courses; fewer than 1% develop chronic kidney disease or ESRD. Most children with frequently relapsing disease eventually achieve sustained remission by adolescence.

Adults: also generally good, but with a higher rate of CNI-dependence, more frequent relapses, and occasional progression to CKD — particularly if the underlying diagnosis is actually FSGS that was misclassified due to sampling error on biopsy.

Factors associated with a more complicated course include: age >10 at onset (adults), frequently relapsing disease, steroid dependence, and requirement for multiple immunosuppressive agents. With careful immunosuppressive management, long-term kidney function preservation is expected in true MCD. The distinction from FSGS remains the most clinically important prognostic determinant.

Back to Table of Contents

Research Papers (PubMed searches)

• Minimal change disease nephrotic syndrome children treatment
• Minimal change disease adults corticosteroids outcomes
• Minimal change disease rituximab randomized trial
• Minimal change disease calcineurin inhibitor tacrolimus
• Minimal change disease T-cell pathogenesis cytokines
• Podocyte foot process effacement nephrotic syndrome
• FSGS minimal change disease differential diagnosis biopsy

Back to Table of Contents

References

1. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274. https://doi.org/10.1038/kisup.2012.10
2. Vivarelli M, et al. Minimal Change Disease. Clin J Am Soc Nephrol. 2017;12(2):332–345. PMID: 27940575. https://doi.org/10.2215/CJN.05000516
3. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629–639. PMID: 12944064. https://doi.org/10.1016/S0140-6736(03)14184-0
4. Waldman M, et al. Adult minimal change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445–453. PMID: 17699450. https://doi.org/10.2215/CJN.03531006
5. Ravani P, et al. Rituximab in children with steroid-dependent nephrotic syndrome: a multicentre, open-label, noninferiority, randomised controlled trial. Lancet. 2011;376(9755):1846–1853. PMID: 21062655. https://doi.org/10.1016/S0140-6736(10)61800-0
6. Iijima K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. N Engl J Med. 2014;370(23):2190–2199. PMID: 24897086. https://doi.org/10.1056/NEJMoa1313989
7. Sinha A, Bagga A. Nephrotic syndrome. Indian J Pediatr. 2012;79(8):1045–1055. PMID: 22592826. https://doi.org/10.1007/s12098-012-0776-2
8. Garin EH, et al. Minimal-change disease and its variants: a histological review. Histopathology. 2005;46(5):536–548. PMID: 15842635. https://doi.org/10.1111/j.1365-2559.2005.02060.x
9. Praga M, Morales E. Renal insufficiency and nephrotic syndrome in adults with minimal change nephropathy. Kidney Int. 2006;69(7):1155–1163. PMID: 16467781. https://doi.org/10.1038/sj.ki.5000255
10. Trautmann A, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023;38(3):877–919. PMID: 36269406. https://doi.org/10.1007/s00467-022-05739-3
11. Shieh JJ, Chernin G, Bhimma R, et al. Podocin mutations in sporadic focal segmental glomerulosclerosis appearing in adulthood. Kidney Int. 2003;64(4):1319–1329. PMID: 12969148. https://doi.org/10.1046/j.1523-1755.2003.00217.x
12. Hinkes BG, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet. 2006;38(12):1397–1405. PMID: 17086176. https://doi.org/10.1038/ng1918

Back to Table of Contents

Connections

• Nephrotic Syndrome
• Focal Segmental Glomerulosclerosis
• Membranous Nephropathy
• Glomerulonephritis
• IgA Nephropathy
• Lupus Nephritis
• Acute Kidney Injury
• Chronic Kidney Disease
• Goodpasture Syndrome
• Kidney Function Tests
• Urinalysis